The Latest Erectile Dysfunction Industry Statistics Explained
Globally the Erectile Dysfunction market is expected to grow at a CAGR of ~6.5% during the forecast period 2019-2023.
The statistic indicates that the global market for Erectile Dysfunction (ED) is poised for significant growth with a projected Compound Annual Growth Rate (CAGR) of approximately 6.5% over the forecast period from 2019 to 2023. This growth rate suggests that the market for ED treatments, medications, and related products will experience steady expansion during this time frame. Factors such as increasing awareness about ED, rising prevalence of the condition, advancements in medical technology, and a growing aging population are likely contributing to this expected growth. Pharmaceutical companies, healthcare providers, and other stakeholders in the ED market may see opportunities for innovation, investment, and expansion in order to capitalize on this projected market growth.
By 2025, the global erectile dysfunction drugs market is expected to reach USD 3.2 billion.
The statistic presents a forecast indicating that the worldwide market for erectile dysfunction drugs is projected to grow and reach a valuation of USD 3.2 billion by the year 2025. This estimation suggests a substantial increase in the demand for erectile dysfunction medications over the next few years, likely driven by factors such as an aging population, lifestyle changes, and increasing awareness and acceptance of treatments for this condition. The projected growth of this market signifies opportunities for pharmaceutical companies operating in this sector to expand their product offerings and cater to a growing consumer base seeking treatment for erectile dysfunction.
Approximately 30 million men in the U.S. are affected by erectile dysfunction.
The statistic that approximately 30 million men in the U.S. are affected by erectile dysfunction indicates a common and significant health issue among men in the country. Erectile dysfunction is characterized by the consistent inability to achieve or maintain an erection sufficient for sexual performance, and it can have a variety of physical and psychological causes. This statistic highlights the widespread impact of erectile dysfunction on men’s quality of life and overall well-being. Increased awareness, treatment options, and support systems are critical in addressing this prevalent issue and improving the sexual health and relationships of affected individuals.
The US holds the largest share of the Erectile Dysfunction market, which is expected to reach USD 2,687.6 million by 2023.
This statistic means that the United States currently has the largest portion of the market for products and services related to Erectile Dysfunction (ED), with an expected market value of USD 2,687.6 million by the year 2023. This indicates that the US is a significant player in the global ED market, likely due to factors such as high awareness and acceptance of ED treatments, a large population with access to healthcare services, and a strong pharmaceutical and healthcare industry. The projected growth in the market value further suggests that there is a growing demand for ED products and services, which presents opportunities for businesses operating in this sector to capitalize on the market potential in the US.
Half of men aged 40-70 years old in the U.S. are affected by erectile dysfunction.
The statistic that half of men aged 40-70 years old in the U.S. are affected by erectile dysfunction indicates that a significant proportion of the male population within this age range experience difficulties achieving or maintaining an erection. Erectile dysfunction can have various physical and psychological causes, such as cardiovascular disease, diabetes, stress, or anxiety. This statistic is important for public health awareness and underscores the prevalence of this condition among middle-aged and older men, highlighting the need for healthcare interventions, support, and education to address and manage erectile dysfunction effectively in this demographic group.
60% of men’s success rate using oral erectile dysfunction drugs.
The statistic “60% of men’s success rate using oral erectile dysfunction drugs” indicates that 60% of men who use oral medications for erectile dysfunction experience improved sexual performance or success in achieving and maintaining an erection. This percentage represents the proportion of men who have reported positive outcomes from using such medications. It is important to note that individual responses to erectile dysfunction drugs can vary, and factors such as health conditions, medication adherence, and lifestyle choices can influence the success rate. Nonetheless, the statistic suggests that a majority of men who use oral erectile dysfunction drugs may benefit from improved erectile function.
The erectile dysfunction market in Europe was worth around USD 1.5 billion in 2018.
This statistic indicates that the market for treatments and medications for erectile dysfunction in Europe had a total value of approximately USD 1.5 billion in the year 2018. This figure reflects the amount of money spent on various products and services related to addressing erectile dysfunction within the European market during that particular year. The value of the market provides insight into the significant demand for solutions to this condition, as well as the economic implications and opportunities within the healthcare industry related to erectile dysfunction treatments in Europe.
Penile implants accounted for less than 5% of the total revenue in the erectile dysfunction treatment market.
This statistic indicates that penile implants, a type of treatment for erectile dysfunction, made up a relatively small percentage of the total revenue generated in the market for treating erectile dysfunction. Specifically, less than 5% of the revenue was attributable to penile implants. This suggests that while penile implants are a treatment option for some individuals with erectile dysfunction, they are not as commonly utilized as other available treatments such as medications, therapy, or lifestyle changes. The dominance of other treatment modalities in the market underscores the importance of considering a variety of approaches when addressing erectile dysfunction.
Erectile dysfunction drugs available over-the-counter, making up around EUR 103.3 mn in Europe.
The statistic indicates that the market for erectile dysfunction drugs available over-the-counter in Europe is estimated to be worth around EUR 103.3 million. This suggests a significant demand for non-prescription treatments for erectile dysfunction in the region. The availability of these drugs over-the-counter reflects a growing trend towards greater accessibility and convenience for individuals seeking treatment for this condition. The market size also underscores the economic significance of this sector within the healthcare industry, with potential implications for pharmaceutical companies, retailers, and consumers in Europe.
The injectable drugs for treating erectile dysfunction are expected to gain growth by a CAGR of 4.60% within 2021 to 2026.
The statistic indicates that the market for injectable drugs used in the treatment of erectile dysfunction is projected to experience a Compound Annual Growth Rate (CAGR) of 4.60% from 2021 to 2026. This suggests that over the specified period, there is expected to be a steady increase in the demand and consumption of these drugs. Factors contributing to this growth could include the rising prevalence of erectile dysfunction, increasing awareness and acceptance of treatment options, as well as advancements in medical technology leading to more effective and accessible injectable drugs. The CAGR provides a clear indication of the average annual growth rate over the specified timeframe, offering insights for stakeholders such as healthcare providers, pharmaceutical companies, and investors in understanding and capitalizing on the market opportunities in this sector.
The expected prevalence rate of men’s erection problems in 2025 is 322 million.
The statistic “The expected prevalence rate of men’s erection problems in 2025 is 322 million” indicates the projected number of men experiencing erection problems in the year 2025. This statistic suggests that a significant portion of the male population worldwide may be affected by this health issue. The prevalence rate serves as a key indicator for public health planning and resource allocation, highlighting the importance of addressing this issue on a global scale. With an estimated 322 million men experiencing erection problems in 2025, healthcare systems and policymakers may need to consider implementing strategies to improve awareness, prevention, and treatment options for this common health concern.
Viagra held the largest share, approximately 45%, in the erectile dysfunction market in 2017.
This statistic indicates that in 2017, Viagra dominated the market for erectile dysfunction medication by holding a substantial share of around 45%. This implies that nearly half of the market demand for erectile dysfunction medication was captured by Viagra, positioning it as the leading product within this therapeutic category. The high market share suggests that Viagra was preferred by a significant portion of consumers seeking treatment for erectile dysfunction, possibly due to factors such as brand recognition, effectiveness, safety profile, or marketing efforts. This level of market dominance highlights Viagra’s strong presence and competitive advantage in the erectile dysfunction market during the specified period.
Viagra made more than $1.4 billion in sales in 2016.
The statistic “Viagra made more than $1.4 billion in sales in 2016” represents the total revenue generated by the pharmaceutical product Viagra in the year 2016. This statistic highlights the significant financial success of Viagra as a medication designed to treat erectile dysfunction. With sales exceeding $1.4 billion, Viagra can be identified as a high-demand product within the pharmaceutical industry, showcasing its popularity and widespread use among consumers during that period. This statistic provides valuable insight into the commercial performance and market presence of Viagra as a well-known and profitable medication.
The male aging market is projected to create a higher market for erectile dysfunction with a CAGR of 7.5% in the forthcoming years.
This statistic suggests that the male aging population is expected to drive a growing market demand for erectile dysfunction products and treatments in the coming years, with a projected compound annual growth rate (CAGR) of 7.5%. As men age, they may experience a higher prevalence of conditions such as erectile dysfunction, leading to an increased need for medications, therapies, and healthcare services addressing this issue. The rising awareness and acceptance of seeking help for erectile dysfunction among aging males are likely factors contributing to the projected growth in this market segment. Companies operating in this industry can anticipate an expanding market opportunity and may strategize accordingly to meet the evolving needs of this consumer segment.
Erectile dysfunction increases by 10% for every decade of age i.e., 50% of men in their 50s, 60% of men in their 60s.
This statistic implies that the prevalence of erectile dysfunction (ED) is positively associated with increasing age, with a consistent pattern of increase. Specifically, for every decade of age a man progresses, the likelihood of experiencing ED increases by 10%. This means that by the time men are in their 50s, approximately 50% of them will have ED, and this proportion rises to 60% for men in their 60s. The statistic highlights the significant impact of aging on the occurrence of ED, emphasizing the need for awareness and appropriate interventions for this common condition as men get older.
Erectile dysfunction’s cost to the US healthcare system is expected to rise by $11 billion annually by the year 2025.
The statistic suggests that the projected annual cost of treating erectile dysfunction in the US healthcare system is expected to increase by $11 billion by the year 2025. This rise in cost implies a growing financial burden on the healthcare system due to the increasing prevalence and treatment expenses associated with erectile dysfunction. Factors contributing to this escalation in costs may include an aging population, lifestyle-related risk factors, increased awareness and diagnosis, rising healthcare costs, and advancements in treatment options. This statistic underscores the importance of addressing and managing erectile dysfunction efficiently to mitigate its impact on both individual health and the healthcare system as a whole.
References
0. – https://www.www.medicalnewstoday.com
1. – https://www.www.health.harvard.edu
2. – https://www.www.healthline.com
3. – https://www.www.uclahealth.org
4. – https://www.www.grandviewresearch.com
5. – https://www.www.globenewswire.com
6. – https://www.www.mordorintelligence.com
7. – https://www.www.nbcnews.com
8. – https://www.www.ncbi.nlm.nih.gov
9. – https://www.www.psmarketresearch.com
